Medigene Shares Plunge to Record Low Amid Bankruptcy Uncertainty

Medigene AG shares hit a historic low of €0.024, erasing nearly all market value amid ongoing bankruptcy proceedings and a lack of communication on asset sales.

The stock of German biotech firm Medigene AG experienced a dramatic single-day collapse, shedding nearly a quarter of its value. This plunge, which saw shares trading for mere cents, underscores a profound erosion of investor confidence in the company's ongoing insolvency proceedings.

On Thursday, the share price on the Tradegate exchange plummeted to a historic low of €0.024. This leaves the market capitalization of the once-promising biotechnology company at approximately €469,000. The valuation stands in stark contrast to the hundreds of millions of euros the business commanded just a few years ago, when it was seen as a leader in developing T-cell receptor-based immunotherapies.

Bankruptcy Proceedings Initiated in 2025

The roots of the current crisis trace back to August 1, 2025, when the Munich District Court formally opened insolvency proceedings for Medigene AG and its subsidiary, Medigene Immunotherapies GmbH. This action followed an initial bankruptcy petition filed in April of the same year. Since the court's ruling, insolvency administrator Axel W. Bierbach has been managing the company's assets.

Previous statements indicated that research operations have been partially maintained under his supervision, primarily to preserve the value of the company's intellectual property and patents. However, the market has received no concrete updates regarding the disposal of these assets or any potential process to secure a new investor. This persistent lack of communication is a key driver behind the recent sell-off.

Pennystock Mechanics Amplify Volatility

Trading at such minimal price levels subjects the stock to extreme percentage swings from relatively small transactions. This volatility is further exacerbated by thin trading volumes. The share was moved from the regulated Prime Standard to the less stringent General Standard following the revocation of its listing admission due to the insolvency.

In the absence of reliable information about asset realization or a rescue investment, the equity's valuation is now almost entirely speculative. It hinges on the faint hope that existing shareholders might recover some minimal residual value—a prospect with a historically weak foundation for success in such situations.